Med Page Today
DECEMBER 22, 2023
(MedPage Today) -- The FDA continues its investigation into counterfeit semaglutide (Ozempic) products -- which may still be available for purchase -- and has already seized thousands of units, the agency announced Thursday. In its warning.
Dr. Smith's ECG Blog
DECEMBER 22, 2023
This is a case I had quite a while back. The patient with no prior cardiac history presented in the middle of the night with acute chest pain, and had this ECG recorded during active pain: I did not see any ischemia on this electrocardiogram. It does not look entirely normal, since there are some nonspecific STT abnormalities, such as flattening of the T waves in aVL.
HCPLive
DECEMBER 22, 2023
In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.
DAIC
DECEMBER 22, 2023
milla1cf Fri, 12/22/2023 - 08:21 December 22, 2023 — HeartBeam, Inc., a medical technology company focused on transforming cardiac care through the power of personalized insights, announced significant developments for the use of artificial intelligence (AI) applied to its proprietary vectorelectrocardiography (VECG) technology, including the addition of new leadership and advisory roles.
Medical Xpress - Cardiology
DECEMBER 22, 2023
Rum-laced eggnog, mulled wine, or a hot toddy all sound good around the holidays, but too much imbibing can increase your risk of "holiday heart syndrome," doctors warn.
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. While medical therapy for right-sided heart failure is limited, treatment options for tricuspid regurgitation include surgery and, based on recent developments, several transcatheter interventions.
The New England Journal of Medicine
DECEMBER 22, 2023
A hospitalized poet writes a series of poems that seem possible only when one is near death. Grasping his condition through metaphor, he shares with his doctors an evolving understanding of life’s mysteries.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
DECEMBER 22, 2023
The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis, making it the only medication approved for self-administration via auto-injector pen for this condition.
American College of Cardiology
DECEMBER 22, 2023
The goal of the FAME 3 trial was to demonstrate the noninferiority of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) for patients with three-vessel disease.
HCPLive
DECEMBER 22, 2023
Stacie Bell, PhD, discusses the disagreement between adolescents and parents regarding how lupus impacts daily life.
American College of Cardiology
DECEMBER 22, 2023
What is the prognostic impact of serial N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels in stable patients with chronic heart failure (HF)?
HCPLive
DECEMBER 22, 2023
This endocrine case report from Brady Pregerson, MD, features a woman in her early 50s with a history of type 2 diabetes and hypothyroidism presenting with 5 days of epigastric pain. Can you determine the correct diagnosis?
American College of Cardiology
DECEMBER 22, 2023
The goal of the STOPDAPT-3 trial was to compare the safety and efficacy of an aspirin-free strategy among patients undergoing percutaneous coronary intervention (PCI) or at high bleeding risk.
HCPLive
DECEMBER 22, 2023
Miller discusses the EMERGENT-2 trial and the benefits of xanomeline-trospium for treating adults with schizophrenia, for which the treatment is currently awaiting FDA decision.
American College of Cardiology
DECEMBER 22, 2023
In this week’s View, Dr. Eagle explores the breakthroughs, trends, and major developments in cardiology over the last twelve months.
HCPLive
DECEMBER 22, 2023
The current treatment paradigm might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.
DAIC
DECEMBER 22, 2023
milla1cf Fri, 12/22/2023 - 08:11 December 22, 2023 — Biosense Webster, Inc. , a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , announced the first patient cases with the investigational Dual Energy Thermocool SmartTouch SF Catheter took place as part of the SmartPulse pivotal study for treatment of paroxysmal atrial fibrillation (AFib).
HCPLive
DECEMBER 22, 2023
The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.
American College of Cardiology
DECEMBER 22, 2023
The goal of the I-STOP-AFIB trial was to assess the efficacy of trigger-based testing for atrial fibrillation (AF) versus routine tracking alone among patients with AF.
HCPLive
DECEMBER 22, 2023
Results from the systematic review and meta-analysis demonstrated the positive effect of DAA therapy on overall survival, HCC-free survival, and liver function among patients with HCV decompensated cirrhosis compared to a non-DAA control group.
Physiologically Speaking
DECEMBER 22, 2023
Greetings! Welcome to the Physiology Friday newsletter. This newsletter is brought to you by Examine.com — the best place on the internet for health and nutrition information — and my new eBook, “VO2 Max Essentials.” Details can be found at the end of the post! Physiologically Speaking is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
HCPLive
DECEMBER 22, 2023
These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.
Physiologically Speaking
DECEMBER 22, 2023
Greetings! Welcome to the Physiology Friday newsletter. This newsletter is brought to you by Examine.com — the best place on the internet for health and nutrition information — and my new eBook, “VO2 Max Essentials.” Details can be found at the end of the post! Physiologically Speaking is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
HCPLive
DECEMBER 22, 2023
This research letter highlights opportunities for researchers to develop more innovative treatments for skin disease, especially for conditions that have unmet therapeutic needs.
The American Journal of Cardiology
DECEMBER 22, 2023
Publication date: Available online 21 December 2023 Source: The American Journal of Cardiology Author(s): Luai Madanat, Mohamed Allam, Houman Khalili, Andrew Rabah, Rehan Tariq, Mazen Zamzam, Josep Rodés-Cabau, Thomas Pilgrim, Taishi Okuno, Sammy Elmariah, Philippe Pibarot, Amr E.
HeartRhythm
DECEMBER 22, 2023
The effect of left bundle branch pacing (LBBP) on right ventricular (RV) function is not well known, and there is conflicting evidence regarding whether cardiac resynchronization therapy improves RV function.
Circulation
DECEMBER 22, 2023
Circulation, Ahead of Print. BACKGROUND:Hypertension is a key risk factor for major adverse cardiovascular events but remains difficult to treat in many individuals. Dietary interventions are an effective approach to lower blood pressure (BP) but are not equally effective across all individuals. BP is heritable, and genetics may be a useful tool to overcome treatment response heterogeneity.
European Journal of Heart Failure
DECEMBER 22, 2023
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heart failure (HF) population across the ejection fraction (EF). Methods and Results Patients with HF from the Swedish HF Registry between 2000-2021 were included. Of 91,463 patients (median age 76 years [IQR 67–82]), 98% had at least one among the 17 explored comorbidities (94% at least one CV and 85% at least one non-CV comorbidity).
Journal of Cardiovascular Electrophysiology
DECEMBER 22, 2023
Abstract Atrial fibrillation (AF) is significantly associated with morbidity and mortality and erodes the quality and quantity of life. It is standard of care to treat patients with AF and an increased risk of stroke with oral anticoagulation therapy, but the more daunting question many clinicians face is whether to pursue a “rate-only” or “rhythm” control strategy.
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Background and aims In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real-world (RW) HOCM patients with those enrolled in EXPLORER-HCM and assessing their eligibility to treatment.
HCPLive
DECEMBER 22, 2023
Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.
DAIC
DECEMBER 22, 2023
milla1cf Fri, 12/22/2023 - 08:03 December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation , announced the successful implantation of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”) in a patient with a pacemaker at the University Medical Center of Mainz, Germany.
American College of Cardiology
DECEMBER 22, 2023
Can sex-specific prediction models for atherosclerotic cardiovascular disease (ASCVD) using age and routine laboratory tests be developed and validated?
Expert insights. Personalized for you.
135 
Let's personalize your content